A study from McMaster University found solriamfetol to be the most effective medication for treating excessive daytime sleepiness in OSA patients. While effective, its potential to raise blood pressure is a concern.
Researchers Dena Zeraatkar and Tyler Pitre from McMaster University have discovered that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals suffering from obstructive sleep apnea (OSA).
The standard treatment for OSA is a positive airway pressure (PAP) mask, which employs pressurized air to assist lung airways during sleep. However, with this treatment, there are those who continue to endure EDS. These individuals may find alleviation from their symptoms through the use of anti-fatigue medication.
Zeraatkar and Pitre recently published their results in the journal Annals of Internal Medicine.
“The most important thing that people with OSA should do is use their PAP machine, but if they are still sleepy there are options in the form of medications that can reduce their tiredness,” said first author Tyler Pitre, a resident physician in internal medicine at McMaster University and incoming respirology fellow at the University of Toronto.
“Fifteen to 30 percent of people in North America have a diagnosis of OSA and the prevalence could be much higher as many others are undiagnosed. Many people have symptoms as the condition is highly associated with obesity, which affects a large and increasing number of people in Canada, the United States, and other high-income countries,” he said.
“Among those patients, many will have EDS, which affects their quality of life, making them less productive and also putting them at risk of other psychological issues. Improving this situation is of paramount importance to physicians.”
Pitre said that OSA affects nearly one billion people globally, leaving many of them at risk of EDS.
Zeraatkar and Pitre made their findings by conducting a systematic review of 14 clinical trials of anti-fatigue medications involving 3,085 people, as well as analyzing data from MEDLINE, CENTRAL, EMBASE, and ClinicalTrials.gov in a specific network meta-analysis. They conducted their research from October 2022 to January 2023.
Senior author Zeraatkar said that while solriamfetol is likely the best medication for EDS, the drugs armodafinil–modafinil and pitolisant are also effective in combatting fatigue.
Potential Risks and Considerations
Solriamfetol can also raise blood pressure, especially risky for people with OSA, as many of them also have cardiovascular issues.
“It would be interesting to see how effective these anti-fatigue medications will be for treating related illnesses such as chronic fatigue syndrome and long COVID, now that we know they work for a similar condition,” said Zeraatkar, an assistant professor of the Department of Anesthesia.
Reference: “Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea – A Systematic Review and Network Meta-analysis” by Tyler Pitre, MD, MA; Jasmine Mah, MD, MSc; Sarah Roberts, BHSc; Kairavi Desai, BMSc; Yusing Gu, MD; Clodagh Ryan, MD, Ph.D.; Jason W. Busse, DC, Ph.D. and Dena Zeraatkar, Ph.D., May 2023, Annals of Internal Medicine.
DOI: 10.7326/M22-3473
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.